Should I buy Humana (HUM) stock or is it too late?

Humana · Health Care · price $420

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Morgan Stanley — 69% of its targets hit on this sector (830 calls tested). It aims for $370 (-12 %), call made on August 6, 2026, maturing on August 6, 2027 (69 d ago).

The 12 reliable analysts $488+16 %

The 6 other firms $428+1.8 %

How to read it: the 12 reliable firms are not filtered by optimism — 9 aim above the price, 3 below, hence their $488 median. “The 6 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Humana

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
JP Morgan	77 %	+18.9 %	13	$393 -7%
Barclays	67 %	+17.1 %	6	$582 +38%
Wells Fargo	73 %	+12.6 %	11	$502 +19%
Morgan Stanley	62 %	+11.9 %	21	$370 -12%
Mizuho	44 %	+5.9 %	9	$495 +18%
Piper Sandler	40 %	+4.7 %	5	$254 -40%
Oppenheimer	33 %	-6.5 %	12	$525 +25%
RBC Capital	29 %	-10.5 %	17	$415 -1%

In short — Should you invest in Humana? Is it too late, still worth it? Analysts are fairly positive (56% buy, median target $473, i.e. +13%), and the most reliable on HUM targets even higher. But the valuation is stretched (P/E ~40). We give you both sides, with the numbers — not advice.

✅ Reasons to believe

Median price target $473, i.e. +13% from the current price ($420).
The most reliable firm on HUM, Raymond James (100% hit rate, 2 scored calls), targets $520 (call made on October 12, 2026, maturing on October 12, 2027) (+24%) in its most recent call.
7 analysts rated reliable (≥55% hit rate, beat their sector) are bullish on the stock.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 18 ratings, 8 are neutral.
High valuation (P/E ~40): strong growth is already "priced in", leaving little room for error.
A 12-month target is not a guaranteed path: the price can fall in the meantime.

The analyst consensus on HUM

Median target $473 (+13%) · 18 ratings · Buy consensus

Strong Buy00%

Buy1056%

Hold844%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Humana now?

We won't decide for you. The facts: 56% of analysts rate it a buy, median target $473 (+13%), and Raymond James (most reliable on HUM, 100%) targets $520. Weigh that against valuation (P/E ~40). This is not personalized advice.

Is it too late to invest in Humana?

Not according to analysts: the median target ($473) is still +13% above the current price ($420) (most reliable on HUM: Raymond James, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Humana still worth investing in?

It depends on the gap between the price ($420) and its estimated value: analysts target $473 on median (+13%), with 56% buys (most reliable on HUM: Raymond James, 100%). Cross-check with their real reliability on HUM and the cautions above. Information, not advice.

What's the main risk in buying HUM?

The consensus is not unanimous: of 18 ratings, 8 are neutral.

→ Go deeper: the full Humana profile (consensus, analyst reliability, price target, performance).